Newsletter Signup | Join Community
Targeting BRAF and EGFR Doubles Progression-free Survival in Metastatic Colorectal Cancer.
NSAIDs Decrease Risk of Colorectal Cancer.
Proton Beam Therapy may Improve Outcomes for Rectal Cancer.
NCCN Guidelines® Recommend SIR-Spheres® Y-90 Resin Microspheres
Herceptin® Plus Tykerb® Promising for HER2-Positive Colorectal Cancer
XBiotech Completes Enrollment for Xilonix™ Phase III Registration Study in Europe, US Trial Ongoing
New Biomarkers Might Help Personalize Metastatic Colorectal Cancer Treatment
Cyramza Added to FOLFIRI Delays Disease Progression and Extends Survival for Patients With Advanced Colorectal Cancer
ASCO 2019: Aggressive Chemotherapy Doubles Survival of Patients with Metastatic Colon Cancer
Chemotherapy Regimens Paired with Avastin or Erbitux Extended Survival for Patients with Metastatic Colorectal Cancer